HUYABIO International

Stories

HDAC inhibitor plus nivolumab cuts melanoma progression risk by 27% in Phase 3 trial

Presented Phase 3 data at ESMO on October 23; plans to share the data with the FDA, with no submission filed yet

Adding an oral histone deacetylase (HDAC) inhibitor to nivolumab cut the risk of melanoma progression or death by 27% in a 404-patient Phase 3 trial. Median progression-free survival was 11.7 months with the combination and 7.4 months with nivolumab alone, according to results presented at the European Society for Medical Oncology congress in Madrid.

Updated Oct 30